| Characteristics . | Placebo . | RSVlow . | RSVhigh . | P Value . |
|---|---|---|---|---|
| Patients, n | 24 | 21 | 21 | |
| Age, y | 47.8 ± 1.30 | 49.1 ± 1.46 | 51.9 ± 1.28 | 0.092 |
| Weight, kg | 113 ± 2.66 | 110 ± 3.22 | 106 ± 2.33 | 0.222 |
| BMI, kg/m2 | 34.1 ± 0.770 | 33.4 ± 0.858 | 33.8 ± 0.668 | 0.815 |
| Waist circumference, cm | 116 ± 2.1 | 116 ± 1.9 | 114 ± 2.1 | 0.835 |
| Systolic BP, mm Hg | 150 ± 3.44a | 140 ± 2.34a | 146 ± 2.34 | 0.050 |
| Diastolic BP, mm Hg | 91.3 ± 2.10 | 86.9 ± 1.54 | 89.3 ± 1.68 | 0.236 |
| VAT, cm3b | 2564 ± 113 | 2888 ± 182 | 2823 ± 217 | 0.371 |
| SAT, cm3b | 6486 ± 565 | 5799 ± 304 | 6135 ± 508 | 0.597 |
| VAT/SAT, %b | 45.1 ± 3.88 | 52.5 ± 4.33 | 50.4 ± 4.88 | 0.459 |
| Fasting glucose, mmol/L | 5.79 ± 0.108 | 5.76 ± 0.210 | 5.74 ± 0.125 | 0.966 |
| Insulin, pmol/L | 100 ± 9.33 | 100 ± 13.3 | 89.4 ± 10.0 | 0.737 |
| HOMA-IR | 4.36 ± 0.450 | 4.42 ± 0.662 | 3.87 ± 0.497 | 0.735 |
| Fructosamine, µmol/L | 241 ± 3.10 | 261 ± 5.38c | 241 ± 3.11 | 0.001 |
| Total cholesterol, mmol/L | 5.81 ± 0.233 | 5.38 ± 0.204 | 5.78 ± 0.232 | 0.336 |
| HDL, mmol/L | 1.19 ± 0.043 | 1.20 ± 0.055 | 1.27 ± 0.073 | 0.563 |
| LDL, mmol/L | 3.71 ± 0.208 | 3.30 ± 0.156 | 3.53 ± 0.249 | 0.367 |
| Triglyceride, mmol/L | 1.7 (1.25, 2.40) | 1.7 (1.10, 2.10) | 1.8 (1.30, 2.30) | 0.577 |
| IHLd | 0.230 ± 0.0350 | 0.231 ± 0.0380 | 0.254 ± 0.0395 | 0.875 |
| ALT, U/L | 40.2 ± 3.53 | 39.5 ± 2.84 | 42.1 ± 2.88 | 0.838 |
| IMCL | 6.84 ± 1.00 | 5.66 ± 0.726 | 5.81 ± 0.855 | 0.577 |
| Lean mass, g | 76,736 ± 1420e | 74,284 ± 1406 | 71,503 ± 1608e | 0.048 |
| Fat mass, g | 35,433 ± 1673 | 35,612 ± 2038 | 33,827 ± 1209 | 0.718 |
| Fat, % | 31.3 ± 0.881 | 32.0 ± 0.957 | 32.0 ± 0.732 | 0.746 |
| Leptin, ng/mL | 13.7 (9.75, 21.1) | 15.3 (11.8, 17.2) | 16.0 (12.6, 20.0) | 0.806 |
| hs-CRP, mg/L | 3.55 (2.05, 6.25) | 2.70 (1.90, 4.70) | 2.30 (1.30, 3.90) | 0.586 |
| Adiponectin, ng/mL | 6766 ± 580 | 7844 ± 532 | 6323 ± 533 | 0.155 |
| IL-6, pg/mL | 1.39 (0.733, 2.05) | 1.44 (1.06, 2.20) | 1.32 (0.704, 2.15) | 0.503 |
| suPAR, ng/mL | 2.74 ± 0.082 | 3.00 ± 0.166 | 2.71 ± 0.137 | 0.236 |
| Characteristics . | Placebo . | RSVlow . | RSVhigh . | P Value . |
|---|---|---|---|---|
| Patients, n | 24 | 21 | 21 | |
| Age, y | 47.8 ± 1.30 | 49.1 ± 1.46 | 51.9 ± 1.28 | 0.092 |
| Weight, kg | 113 ± 2.66 | 110 ± 3.22 | 106 ± 2.33 | 0.222 |
| BMI, kg/m2 | 34.1 ± 0.770 | 33.4 ± 0.858 | 33.8 ± 0.668 | 0.815 |
| Waist circumference, cm | 116 ± 2.1 | 116 ± 1.9 | 114 ± 2.1 | 0.835 |
| Systolic BP, mm Hg | 150 ± 3.44a | 140 ± 2.34a | 146 ± 2.34 | 0.050 |
| Diastolic BP, mm Hg | 91.3 ± 2.10 | 86.9 ± 1.54 | 89.3 ± 1.68 | 0.236 |
| VAT, cm3b | 2564 ± 113 | 2888 ± 182 | 2823 ± 217 | 0.371 |
| SAT, cm3b | 6486 ± 565 | 5799 ± 304 | 6135 ± 508 | 0.597 |
| VAT/SAT, %b | 45.1 ± 3.88 | 52.5 ± 4.33 | 50.4 ± 4.88 | 0.459 |
| Fasting glucose, mmol/L | 5.79 ± 0.108 | 5.76 ± 0.210 | 5.74 ± 0.125 | 0.966 |
| Insulin, pmol/L | 100 ± 9.33 | 100 ± 13.3 | 89.4 ± 10.0 | 0.737 |
| HOMA-IR | 4.36 ± 0.450 | 4.42 ± 0.662 | 3.87 ± 0.497 | 0.735 |
| Fructosamine, µmol/L | 241 ± 3.10 | 261 ± 5.38c | 241 ± 3.11 | 0.001 |
| Total cholesterol, mmol/L | 5.81 ± 0.233 | 5.38 ± 0.204 | 5.78 ± 0.232 | 0.336 |
| HDL, mmol/L | 1.19 ± 0.043 | 1.20 ± 0.055 | 1.27 ± 0.073 | 0.563 |
| LDL, mmol/L | 3.71 ± 0.208 | 3.30 ± 0.156 | 3.53 ± 0.249 | 0.367 |
| Triglyceride, mmol/L | 1.7 (1.25, 2.40) | 1.7 (1.10, 2.10) | 1.8 (1.30, 2.30) | 0.577 |
| IHLd | 0.230 ± 0.0350 | 0.231 ± 0.0380 | 0.254 ± 0.0395 | 0.875 |
| ALT, U/L | 40.2 ± 3.53 | 39.5 ± 2.84 | 42.1 ± 2.88 | 0.838 |
| IMCL | 6.84 ± 1.00 | 5.66 ± 0.726 | 5.81 ± 0.855 | 0.577 |
| Lean mass, g | 76,736 ± 1420e | 74,284 ± 1406 | 71,503 ± 1608e | 0.048 |
| Fat mass, g | 35,433 ± 1673 | 35,612 ± 2038 | 33,827 ± 1209 | 0.718 |
| Fat, % | 31.3 ± 0.881 | 32.0 ± 0.957 | 32.0 ± 0.732 | 0.746 |
| Leptin, ng/mL | 13.7 (9.75, 21.1) | 15.3 (11.8, 17.2) | 16.0 (12.6, 20.0) | 0.806 |
| hs-CRP, mg/L | 3.55 (2.05, 6.25) | 2.70 (1.90, 4.70) | 2.30 (1.30, 3.90) | 0.586 |
| Adiponectin, ng/mL | 6766 ± 580 | 7844 ± 532 | 6323 ± 533 | 0.155 |
| IL-6, pg/mL | 1.39 (0.733, 2.05) | 1.44 (1.06, 2.20) | 1.32 (0.704, 2.15) | 0.503 |
| suPAR, ng/mL | 2.74 ± 0.082 | 3.00 ± 0.166 | 2.71 ± 0.137 | 0.236 |
Results are expressed as mean ± SEM or as median (interquartile range) with a P value from the overall ANOVA. In case of a significant finding in the ANOVA, post hoc Sidak multiple comparisons were used to identify which group means were significantly different.
Abbreviations: ALT, alanine aminotransferase; HDL, high-density lipoprotein; IMCL, intramyocellular lipid content; suPAR, soluble urokinase plasminogen activator receptor.
Values for placebo and RSVlow groups in this row are significantly different at P < 0.05.
Placebo group (n = 22), RSVlow (n = 20), and RSVhigh (n = 20).
Value for RSVlow group differs significantly, at P < 0.05, from the values for the placebo and RSVhigh groups in this row.
Placebo group (n = 24), RSVlow (n = 20), and RSVhigh (n = 21).
Values for placebo and RSVhigh groups in this row are significantly different at P < 0.05.
| Characteristics . | Placebo . | RSVlow . | RSVhigh . | P Value . |
|---|---|---|---|---|
| Patients, n | 24 | 21 | 21 | |
| Age, y | 47.8 ± 1.30 | 49.1 ± 1.46 | 51.9 ± 1.28 | 0.092 |
| Weight, kg | 113 ± 2.66 | 110 ± 3.22 | 106 ± 2.33 | 0.222 |
| BMI, kg/m2 | 34.1 ± 0.770 | 33.4 ± 0.858 | 33.8 ± 0.668 | 0.815 |
| Waist circumference, cm | 116 ± 2.1 | 116 ± 1.9 | 114 ± 2.1 | 0.835 |
| Systolic BP, mm Hg | 150 ± 3.44a | 140 ± 2.34a | 146 ± 2.34 | 0.050 |
| Diastolic BP, mm Hg | 91.3 ± 2.10 | 86.9 ± 1.54 | 89.3 ± 1.68 | 0.236 |
| VAT, cm3b | 2564 ± 113 | 2888 ± 182 | 2823 ± 217 | 0.371 |
| SAT, cm3b | 6486 ± 565 | 5799 ± 304 | 6135 ± 508 | 0.597 |
| VAT/SAT, %b | 45.1 ± 3.88 | 52.5 ± 4.33 | 50.4 ± 4.88 | 0.459 |
| Fasting glucose, mmol/L | 5.79 ± 0.108 | 5.76 ± 0.210 | 5.74 ± 0.125 | 0.966 |
| Insulin, pmol/L | 100 ± 9.33 | 100 ± 13.3 | 89.4 ± 10.0 | 0.737 |
| HOMA-IR | 4.36 ± 0.450 | 4.42 ± 0.662 | 3.87 ± 0.497 | 0.735 |
| Fructosamine, µmol/L | 241 ± 3.10 | 261 ± 5.38c | 241 ± 3.11 | 0.001 |
| Total cholesterol, mmol/L | 5.81 ± 0.233 | 5.38 ± 0.204 | 5.78 ± 0.232 | 0.336 |
| HDL, mmol/L | 1.19 ± 0.043 | 1.20 ± 0.055 | 1.27 ± 0.073 | 0.563 |
| LDL, mmol/L | 3.71 ± 0.208 | 3.30 ± 0.156 | 3.53 ± 0.249 | 0.367 |
| Triglyceride, mmol/L | 1.7 (1.25, 2.40) | 1.7 (1.10, 2.10) | 1.8 (1.30, 2.30) | 0.577 |
| IHLd | 0.230 ± 0.0350 | 0.231 ± 0.0380 | 0.254 ± 0.0395 | 0.875 |
| ALT, U/L | 40.2 ± 3.53 | 39.5 ± 2.84 | 42.1 ± 2.88 | 0.838 |
| IMCL | 6.84 ± 1.00 | 5.66 ± 0.726 | 5.81 ± 0.855 | 0.577 |
| Lean mass, g | 76,736 ± 1420e | 74,284 ± 1406 | 71,503 ± 1608e | 0.048 |
| Fat mass, g | 35,433 ± 1673 | 35,612 ± 2038 | 33,827 ± 1209 | 0.718 |
| Fat, % | 31.3 ± 0.881 | 32.0 ± 0.957 | 32.0 ± 0.732 | 0.746 |
| Leptin, ng/mL | 13.7 (9.75, 21.1) | 15.3 (11.8, 17.2) | 16.0 (12.6, 20.0) | 0.806 |
| hs-CRP, mg/L | 3.55 (2.05, 6.25) | 2.70 (1.90, 4.70) | 2.30 (1.30, 3.90) | 0.586 |
| Adiponectin, ng/mL | 6766 ± 580 | 7844 ± 532 | 6323 ± 533 | 0.155 |
| IL-6, pg/mL | 1.39 (0.733, 2.05) | 1.44 (1.06, 2.20) | 1.32 (0.704, 2.15) | 0.503 |
| suPAR, ng/mL | 2.74 ± 0.082 | 3.00 ± 0.166 | 2.71 ± 0.137 | 0.236 |
| Characteristics . | Placebo . | RSVlow . | RSVhigh . | P Value . |
|---|---|---|---|---|
| Patients, n | 24 | 21 | 21 | |
| Age, y | 47.8 ± 1.30 | 49.1 ± 1.46 | 51.9 ± 1.28 | 0.092 |
| Weight, kg | 113 ± 2.66 | 110 ± 3.22 | 106 ± 2.33 | 0.222 |
| BMI, kg/m2 | 34.1 ± 0.770 | 33.4 ± 0.858 | 33.8 ± 0.668 | 0.815 |
| Waist circumference, cm | 116 ± 2.1 | 116 ± 1.9 | 114 ± 2.1 | 0.835 |
| Systolic BP, mm Hg | 150 ± 3.44a | 140 ± 2.34a | 146 ± 2.34 | 0.050 |
| Diastolic BP, mm Hg | 91.3 ± 2.10 | 86.9 ± 1.54 | 89.3 ± 1.68 | 0.236 |
| VAT, cm3b | 2564 ± 113 | 2888 ± 182 | 2823 ± 217 | 0.371 |
| SAT, cm3b | 6486 ± 565 | 5799 ± 304 | 6135 ± 508 | 0.597 |
| VAT/SAT, %b | 45.1 ± 3.88 | 52.5 ± 4.33 | 50.4 ± 4.88 | 0.459 |
| Fasting glucose, mmol/L | 5.79 ± 0.108 | 5.76 ± 0.210 | 5.74 ± 0.125 | 0.966 |
| Insulin, pmol/L | 100 ± 9.33 | 100 ± 13.3 | 89.4 ± 10.0 | 0.737 |
| HOMA-IR | 4.36 ± 0.450 | 4.42 ± 0.662 | 3.87 ± 0.497 | 0.735 |
| Fructosamine, µmol/L | 241 ± 3.10 | 261 ± 5.38c | 241 ± 3.11 | 0.001 |
| Total cholesterol, mmol/L | 5.81 ± 0.233 | 5.38 ± 0.204 | 5.78 ± 0.232 | 0.336 |
| HDL, mmol/L | 1.19 ± 0.043 | 1.20 ± 0.055 | 1.27 ± 0.073 | 0.563 |
| LDL, mmol/L | 3.71 ± 0.208 | 3.30 ± 0.156 | 3.53 ± 0.249 | 0.367 |
| Triglyceride, mmol/L | 1.7 (1.25, 2.40) | 1.7 (1.10, 2.10) | 1.8 (1.30, 2.30) | 0.577 |
| IHLd | 0.230 ± 0.0350 | 0.231 ± 0.0380 | 0.254 ± 0.0395 | 0.875 |
| ALT, U/L | 40.2 ± 3.53 | 39.5 ± 2.84 | 42.1 ± 2.88 | 0.838 |
| IMCL | 6.84 ± 1.00 | 5.66 ± 0.726 | 5.81 ± 0.855 | 0.577 |
| Lean mass, g | 76,736 ± 1420e | 74,284 ± 1406 | 71,503 ± 1608e | 0.048 |
| Fat mass, g | 35,433 ± 1673 | 35,612 ± 2038 | 33,827 ± 1209 | 0.718 |
| Fat, % | 31.3 ± 0.881 | 32.0 ± 0.957 | 32.0 ± 0.732 | 0.746 |
| Leptin, ng/mL | 13.7 (9.75, 21.1) | 15.3 (11.8, 17.2) | 16.0 (12.6, 20.0) | 0.806 |
| hs-CRP, mg/L | 3.55 (2.05, 6.25) | 2.70 (1.90, 4.70) | 2.30 (1.30, 3.90) | 0.586 |
| Adiponectin, ng/mL | 6766 ± 580 | 7844 ± 532 | 6323 ± 533 | 0.155 |
| IL-6, pg/mL | 1.39 (0.733, 2.05) | 1.44 (1.06, 2.20) | 1.32 (0.704, 2.15) | 0.503 |
| suPAR, ng/mL | 2.74 ± 0.082 | 3.00 ± 0.166 | 2.71 ± 0.137 | 0.236 |
Results are expressed as mean ± SEM or as median (interquartile range) with a P value from the overall ANOVA. In case of a significant finding in the ANOVA, post hoc Sidak multiple comparisons were used to identify which group means were significantly different.
Abbreviations: ALT, alanine aminotransferase; HDL, high-density lipoprotein; IMCL, intramyocellular lipid content; suPAR, soluble urokinase plasminogen activator receptor.
Values for placebo and RSVlow groups in this row are significantly different at P < 0.05.
Placebo group (n = 22), RSVlow (n = 20), and RSVhigh (n = 20).
Value for RSVlow group differs significantly, at P < 0.05, from the values for the placebo and RSVhigh groups in this row.
Placebo group (n = 24), RSVlow (n = 20), and RSVhigh (n = 21).
Values for placebo and RSVhigh groups in this row are significantly different at P < 0.05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
